Emerald Bioscience Inc. announced the appointment of Margaret R. Dalesandro to the Company's Board of Directors. Dr. Dalesandro brings more than 25 years of drug development experience in pharmaceutical, biotechnology and diagnostics companies. Dr. Dalesandro previously served as Business Director of Corning Integrative Pharmacology. Prior to that, as Vice President of Business Development and Portfolio Management at ImClone Systems Inc., she led the building of comprehensive development plans (from toxicology to market) for the use of Ramucirumab (a fully human VEGFR2 antibody) in age-related macular degeneration, and subsequently led negotiations to out-license a Ramicirumab Fab fragment to a major pharmaceutical company specializing in ophthalmic drug indications.